Sarcopenia in oncologic patients in palliative care: an integrative review            /              Sarcopenia em pacientes oncológicos em cuidados paliativos: uma revisão integrativa

Renan Gondim Araújo; Raquel Bezerra Barbosa de Moura; Adriana Gomes Cézar de Carvalho; Luciana Maria Martinez Vaz; Ângelo Brito Pereira Melo; Fábio Correia Sampaio

doi:10.9789/2175-5361.rpcfo.v12.9494

Autores

Renan Gondim Araújo Hospital Universitário Lauro Wanderley da Universidade Federal da Paraíba
Raquel Bezerra Barbosa de Moura Hospital Universitário Lauro Wanderley da Universidade Federal da Paraíba
Adriana Gomes Cézar de Carvalho Hospital Universitário Lauro Wanderley da Universidade Federal da Paraíba
Luciana Maria Martinez Vaz Faculdade de Ciências Médicas da Paraíba
Ângelo Brito Pereira Melo Hospital Universitário Lauro Wanderley da Universidade Federal da Paraíba
Fábio Correia Sampaio Hospital Universitário Lauro Wanderley da Universidade Federal da Paraíba

DOI:

https://doi.org/10.9789/2175-5361.rpcfo.v12.9494

Palavras-chave:

Cuidados Paliativos, Neoplasias, Composição corporal, Sobrevida, Qualidade de vida.

Resumo

Objetivo: Analisar a produção científica acerca das consequências da sarcopenia em pacientes oncológicos em cuidados paliativos. Metodologia: Revisão integrativa, sendo realizado o levantamento bibliográfico por meio de busca eletrônica na Biblioteca Virtual de Saúde, Pubmed, LILACS e SciELO, utilizando os descritores controlados “sarcopenia”, “cuidados paliativos” e “câncer”, associados pelos operadores booleanos “AND” e “OR”. Resultados: Foram incluídos 18 artigos, dos quais foram extraídas três abordagens temáticas que tratam sobre a prevalência e fatores associados à sarcopenia, e sua influência na sobrevida, qualidade de vida e sintomas em pacientes oncológicos em cuidados paliativos. Conclusão: A sarcopenia nestes pacientes possui alta prevalência, leva ao maior risco de toxicidade à quimioterapia paliativa com influência na sobrevida, e, ainda, está relacionada a uma maior carga de sintomas, contribuindo para malograr a qualidade de vida desses pacientes, sendo necessária a discussão sobre o combate da sarcopenia durante o curso da doença oncológica.

Downloads

Não há dados estatísticos.

Referências

Campolina AG, Adami F, Santos JLF, Lebrão ML. A transição de saúde e as mudanças na expectativa de vida saudável da população idosa : possíveis impactos da prevenção de doenças crônicas. Cad Saúde Pública. 2013;29(6):1217–29.

Brasil. Instituto Nacional de Câncer-INCA, Estimativas da incidência e mortalidade por câncer. Ministério da Saúde. 2018. 128 p.

Matsumoto DY. Cuidados paliativos: conceito, fundamentos e princípios. Carvalho RT, Parsons HÁ, Organizadores. Manual de cuidados paliativos ANCP: Ampliado e atualizado. 2. ed. Acad Nac Cuid Paliativos; 2012. p. 23-30.

Rosenberg IH. Summary comments. Surg Oncol. 1989;19(2):61.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised european consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.

Souza MT, Silva MD, Carvalho R. Revisão integrativa: o que é e como fazer. Einstein. 2010;8(1):102–6.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1).

Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019; 10(4): 803-813.

Silva JR, Wiegert EVM, Oliveira L, Calixto-Lima L. Different methods for diagnosis of sarcopenia and its association with nutritional status and survival in patients with advanced cancer in palliative care. Nutrition. 2019;60:48–52.

Nipp RD, Fuchs G, El‐Jawahri A, Mario J, Troschel FM, Greer JA, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist. 2018;23(1):97–104.

Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, et al. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2018;9(5):909–19.

Versteeg KS, Blauwhoff‐Buskermolen S, Buffart LM, Van der Schueren MAE, Langius JAE, Verheul HMW, et al. Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist. 2018;23(5):580–5.

Queiroz MSC, Wiegert EVM, Lima LC, Oliveira LC. Associação entre sarcopenia, estado nutricional e qualidade de vida em pacientes com câncer avançado em cuidados paliativos. Rev Bras Cancerol. 2018;64(1):69–75.

Neefjes ECW, Van den Hurk RM, Blauwhoff-Buskermolen S, van der Vorst MJDL, Becker-Commissaris A, de van der Schueren MAE, et al. Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):623–9.

Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759–67.

Rier HN, Jager A, Sleijfer S, Van Rosmalen J, Kock MCJM, Levin MD. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast. 2017;31:9–15.

Pérez Camargo DA, Allende Pérez SR, Verastegui Avilés E, Rivera Franco MM, Meneses García A, Herrera Gómez Á, et al. Assessment and impact of phase angle and sarcopenia in palliative cancer patients. Nutr Cancer. 2017;69(8):1227–33.

Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016;35(6):1386–93.

Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im SA, et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One. 2015;10(10):1–13.

Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol (Madr). 2015;54(3):340–8.

Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013;21(12):3261–70.

Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Birdsell L, et al. The association of nutritional assessment criteria with health-related quality of life in patients with advanced colorectal carcinoma. Eur J Cancer Care (Engl). 2012;21(4):505–16.

Mir O, Coriat R, Dhooge M, Perkins G, Boudou-Rouquette P, Brezault C, et al. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anticancer Drugs. 2012;23(7):739–44.

Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I AS. Body composition in patients with non–small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91:1133S–1137S.

Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KCH. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15(22):6973–9.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011;12(5):489–95.

Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.

Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr. 2013;98(4):1012–9.

Solheim TS, Laird BJA. Evidence base for multimodal therapy in cachexia. Curr Opin Support Palliat Care. 2012;6(4):424–31.

Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5(4):607–16.

Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–84.